Price T Rowe Associates Inc Aclaris Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 139,400 shares of ACRS stock, worth $165,886. This represents 0.0% of its overall portfolio holdings.
Number of Shares
139,400
Previous 109,767
27.0%
Holding current value
$165,886
Previous $137,000
12.41%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding ACRS
# of Institutions
100Shares Held
52.2MCall Options Held
32.4KPut Options Held
3.3K-
Bml Capital Management, LLC Zionsville, IN13MShares$15.5 Million10.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.69MShares$5.58 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.34MShares$3.97 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY3.32MShares$3.95 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.75MShares$3.28 Million0.09% of portfolio
About Aclaris Therapeutics, Inc.
- Ticker ACRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 66,671,800
- Market Cap $79.3M
- Description
- Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...